August 30 – Shanghai Fosun Pharmaceutical (600196) recorded a 57.2-percent year-on-year growth in interim net profits to 867 million yuan, reports yicai.com, citing a company filing. EPS hit 0.46 yuan during that period. Revenues rose 41.4 percent year-on-year to 3.1 billion yuan, of which pharmaceutical distribution and retail business together accounted for 723 million yuan, up 34.71 percent.

Fosun Pharmaceutical said investments in Shanghai Tofflon Science and Technology (300171), Shandong Jincheng Pharmaceutical and Chemical (300233), Zhejiang D.A Diagnostics (300244) and Henan Billions Chemicals (002601) went public with no disclosure of returns.

Source:capitalvue